Avecho Biotechnology Limited

Equities

AVE

AU0000047441

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:38 2024-05-17 am EDT			5-day change	1st Jan Change
0.003 ^AUD	0.00%		-25.00%	-14.29%

May. 16	Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial	MT
Mar. 25	Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial	MT

Phosphagenics Limited Announces Management Changes, Effective from April 1, 2019

March 26, 2019 at 06:06 pm EDT

On 27 March 2019, Phosphagenics announced that Dr. Ross Murdoch will step down from his role as Chief Executive Officer, and becoming a Non-Executive Director effective April 1, 2019. The Board had agreed to the early release from his six-month notice period, in exchange for Dr. Murdoch releasing Phosphagenics from paying any outstanding contractual entitlements. Dr. Greg Collier will assume the role of Executive Chairman from Non-Executive Chairman, effective April 1, 2019 and will be closely supported by Dr. Paul Gavin (Chief Scientific Officer) and Dr. Roksan Libinaki (GM Animal Health & Production) who will make up the Executive Management team.

Latest news about Avecho Biotechnology Limited

Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial	May. 15	MT
Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial	Mar. 25	MT
Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug	Mar. 14	MT
Avecho Biotechnology Secures Ethics Clearance for Phase Three Insomnia Trial	Mar. 07	MT
Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Avecho Biotechnology Achieves Two-Year Stability Milestone for CBD Capsule	23-06-21	MT
US Patent Office Allows Avecho Biotechnology's Patent on 'Optimized' Manufacturing Method for Tocopheryl Phosphate Mixture	23-05-28	MT
Avecho Biotechnology Signs Licensing Deal with Arthur Group for Development of Cancer Drugs	23-05-22	MT
Avecho Biotechnology Begins Manufacturing for Oral Cannabidiol Capsules	23-05-17	MT
Avecho Biotechnology Raises AU$2 Million Via Entitlement Offer; Shares Slip 20%	23-05-08	MT
Avecho Biotechnology Conducts Entitlement Offer to Raise $11 Million to Fund Pivotal Phase Iii Clinical Trial	23-04-02	CI
Avecho Biotechnology Limited Auditor Raises 'Going Concern' Doubt	23-03-14	CI
Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Avecho Biotechnology Expands Research Partnership for Cannabidiol Medication	23-02-22	MT
Avecho Biotechnology Limited Announces Ongoing Collaboration with Lambert Initiative	23-02-21	CI
Athenex Pharmaceutical Division Submits Avecho's Vitamin K Injection to US FDA	23-01-12	MT
Athenex Submits Avecho's Phytonadione to FDA Pre-IND	23-01-11	CI
Avecho Biotechnology Secures Ethics Approval for Phase 3 Insomnia Trial	22-12-22	MT
Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia	22-12-21	CI
Avecho Biotechnology Signs Development Deal for TPM-enhanced Ibuprofen Gel for US market; Shares Up 10%	22-12-20	MT
Avecho Biotechnology Limited Signs Development Agreement with Perrigo Company plc	22-12-19	CI
Avecho Biotechnology Validates Bioavailability of Cannabinoid Product in Canine Study	22-09-19	MT
Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk	22-09-18	CI
Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-28	CI

Chart Avecho Biotechnology Limited

Duration

Period

More charts

Company Profile

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVECHO BIOTECHNOLOGY LIMITED	-14.29%	6.35M
MODERNA, INC.	+33.01%	50.85B
IQVIA HOLDINGS INC.	+0.36%	42.82B
LONZA GROUP AG	+49.62%	42.03B
CELLTRION, INC.	-4.96%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.12%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.93%	19.13B
BIO-TECHNE CORPORATION	+8.70%	13.05B
MEDPACE HOLDINGS, INC.	+27.74%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.71%	12.08B

Other Biotechnology & Medical Research